Articles related to CANCER SCREENING

The FDA approved Freenome’s SimpleScreen CRC blood test for colorectal cancer screening in average-risk adults. Clinical study results showed the test detected roughly 80% of colorectal cancers, though current guidelines continue to favor colonoscopy and stool-based screening options.

A two-year analysis of 12,670 screened men found that the Stockholm3 risk model detected more clinically significant prostate cancers than PSA testing alone, primarily through fewer false-negative results. The findings suggest improved screening discrimination, although follow-up remains limited to two years.

A multivariable screening test detects 90% of clinically significant prostate cancers vs 74% with PSA alone, suggesting PSA thresholds may miss aggressive disease despite similar false-positive rates.

Nearly 18 million US women aged 45–64 were overdue for at least one recommended breast, cervical, or colorectal cancer screening, with colorectal cancer representing the largest unmet need in a 2024 BRFSS analysis of 36.2 million women.

“The extended-hours model was effective… early morning dose, in-center observation, overnight remote monitoring equipment, and next-day follow-up cut the need for extended shifts and differential pay.”

The American Cancer Society updated its colorectal cancer screening guidelines to include two new multitarget stool tests and a blood-based option, while maintaining colonoscopy as the gold standard and the age-45 screening initiation recommendation for average-risk adults.